Lung Cancer

Behavioral economics is a tool that can influence patient behaviors using concepts such as choice architecture, nudges, and loss aversion.

The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Poziotinib is an irreversible pan HER2 inhibitor with activity against mutations of HER1, HER2, and HER4.

Approximately one-third of the individuals had an intracranial response among those with central nervous system metastases.

Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.

About one-third of participants in the phase 1b cohort of the KRYSTAL-1 study show an intracranial response, according to Mirati Therapeutics.

Crizotinib has also been approved to treat non-small cell lung cancer that has spread to other parts of the body and is caused by a defect in either the ALK or ROS1 gene.

Metformin has been shown to decrease pro-inflammatory cytokines that appear to improve the immune response to tumor cells and improve the efficacy of immunotherapy.

Treatment identifies patients with ROS1 fusion-positive non-small cell lung cancer or those with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek may be appropriate.

Social determinants of health (SDOH), which include social, economic, and physical conditions, have a major impact on people’s health, wellbeing, and quality of life.

Selpercatinib (Retevmo, Loxo Oncology) is FDA-approved to treat 3 types of tumors—metastatic RET fusion-positive non-small cell lung cancer, advanced medullary thyroid cancer (MTC) or MTC that has spread, and advanced RET fusion-positive thyroid cancer.

Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the immune system to detect and fight tumor cells.

Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response.

An immune checkpoint inhibitor plus ramucirumab found to improve overall survival versus standard of care in patients with advanced non-small cell lung cancer.

Uliledlimab plus toripalimab (Tuoyi) shows significant response rates in patients with advanced non–small cell lung cancer previously ineligible to receive standard-of-care treatment.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

The agent is the first oral therapy for this indication.

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.